H

TuHURA Biosciences Inc
D

HURA

2.69000
USD
-0.08
(-2.89%)
مغلق
حجم التداول
4,196
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
125,215,643
المقالات

العنوان: TuHURA Biosciences Inc

القطاع: Healthcare
الصناعة: Biotechnology
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.